Tenapanor offers opportunity to address two long-standing unmet needs, says analyst

12 November 2020

Tenapanor therapy for hyperphosphatemia (HP) in chronic kidney disease (CKD) patients who are on dialysis is likely to gain a front-line position in the CKD-HP market, says analyst.

This is due both to its novel mechanism of action (MoA) and its opportunity to address low patient compliance for those on HP monotherapy and the need for therapies targeting refractory CKD-HP - two long-standing unmet needs in the space, according to data and analytics company GlobalData.

The drug is under development by US biopharma company Ardelyx (Nasdaq: ARDX) in partnership with Japan’s Kyowa Hakko Kirin (TYO: 4151). In September 2019, tenapanor was approved in the USA under the trade name Ibsrela for the treatment of irritable bowel syndrome with constipation.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK